-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Sees Significant Decrease in Short Interest
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Sees Significant Decrease in Short Interest
Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 111,700 shares, a decline of 5.7% from the December 15th total of 118,500 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.4% of the shares of the company are short sold.
Dermata Therapeutics Stock Up 15.0 %
Shares of DRMA opened at $0.29 on Monday. Dermata Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.45. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.56.
Get Dermata Therapeutics alerts:Dermata Therapeutics (NASDAQ:DRMA – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Dermata Therapeutics will post -0.82 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have commented on DRMA shares. Brookline Capital Management reiterated a "buy" rating on shares of Dermata Therapeutics in a research report on Monday, October 3rd. Maxim Group reduced their price objective on shares of Dermata Therapeutics from $4.00 to $1.00 in a research note on Tuesday, December 6th.Institutional Trading of Dermata Therapeutics
A hedge fund recently bought a new stake in Dermata Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,808 shares of the company's stock, valued at approximately $37,000. Virtu Financial LLC owned 0.70% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.63% of the stock is owned by hedge funds and other institutional investors.
About Dermata Therapeutics
(Get Rating)
Dermata Therapeutics, Inc, a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
See Also
- Get a free copy of the StockNews.com research report on Dermata Therapeutics (DRMA)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 111,700 shares, a decline of 5.7% from the December 15th total of 118,500 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.4% of the shares of the company are short sold.
Dermata Therapeutics, Inc.(纳斯达克股票代码:DRMA — Get Rating)是12月空头利率大幅下降的受益者。截至12月30日,空头利率共计111,700股,较12月15日的11.85万股下降了5.7%。根据1,640,000股的平均每日交易量,目前的天数与覆盖率为0.1天。该公司约有1.4%的股份被卖空。
Dermata Therapeutics Stock Up 15.0 %
Dermata Therapeutics 股票上涨了 15.0%
Shares of DRMA opened at $0.29 on Monday. Dermata Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.45. The business has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.56.
周一,DRMA的股价开盘价为0.29美元。Dermata Therapeutics创下12个月低点0.16美元,12个月高点为2.45美元。该公司的50天简单移动平均线为0.37美元,两百天的简单移动平均线为0.56美元。
Dermata Therapeutics (NASDAQ:DRMA – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Dermata Therapeutics will post -0.82 EPS for the current fiscal year.
Dermata Therapeutics(纳斯达克股票代码:DRMA — 获取评级)上次公布季度财报是在11月10日星期四。该公司报告了本季度每股收益(EPS)(0.20美元)。总体而言,分析师预计,Dermata Therapeutics将在本财年公布每股收益为-0.82。
Wall Street Analysts Forecast Growth
华尔街分析师预测增长
Institutional Trading of Dermata Therapeutics
Dermata Therapeutics 的机构交易
A hedge fund recently bought a new stake in Dermata Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,808 shares of the company's stock, valued at approximately $37,000. Virtu Financial LLC owned 0.70% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 1.63% of the stock is owned by hedge funds and other institutional investors.
一家对冲基金最近购买了Dermata Therapeutics股票的新股份。Virtu Financial LLC在向美国证券交易委员会(SEC)提交的最新13F表格中显示,该公司在第三季度收购了Dermata Therapeutics, Inc.(纳斯达克股票代码:DRMA — Get Rating)的新股份。该公司收购了该公司70,808股股票,价值约37,000美元。截至最近向美国证券交易委员会(SEC)提交文件时,Virtu Financial LLC拥有Dermata Therapeutics0.70%的股份。1.63%的股票由对冲基金和其他机构投资者持有。
About Dermata Therapeutics
关于 Dermata Therapeut
(Get Rating)
(获取评分)
Dermata Therapeutics, Inc, a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Dermata Therapeutics, Inc是一家临床阶段的生物技术公司,专注于识别、开发和商业化用于治疗医学和美容皮肤病的候选药物。该公司的主要候选产品是 DMT310,它已完成治疗中度至重度痤疮的IiB期临床试验;以及针对轻度至中度牛皮癣的Ib期概念验证(POC)试验,以及治疗中度至重度红斑痤疮的2期临床试验。
See Also
另见
- Get a free copy of the StockNews.com research report on Dermata Therapeutics (DRMA)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- 免费获取 StockNews.com 关于 Dermata Therapeutics (DRMA) 的研究报告
- C3.ai Stock 是 ChatGPT 人工智能游戏吗?
- NVIDIA 展望改善:2023 年的关注名单候选人
- 你应该在 2023 年购买哪只无线股票?
- 维珍银河股票正在为起飞做准备吗?
- 雪佛龙可能会在盈利前增加股息
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Dermata Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Dermata Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧